Find endotoxin testing support for your product and its formulation. Creative BioMart provides sample-specific testing services for plasma-derived proteins, recombinant proteins, peptides, vaccines, nucleic acids and other biopharmaceutical preparations. Explore the product families below, identify the most relevant service and share your sample details to define the testing scope.
Product identity provides a starting point for endotoxin testing, but it does not define the complete analytical approach. Two samples containing the same active ingredient can differ in concentration, buffer, excipients, physical form and processing history. These differences can affect sample preparation, assay response and the dilution needed to obtain an interpretable result.
Testing may support research, process development, purification studies or a defined quality testing program. We review the purpose of the work and the target specification before discussing the assay and report. An endotoxin result addresses bacterial endotoxin; it is not a substitute for sterility testing, a complete impurity profile or broader pyrogen evaluation.
Choose the protein family that best describes your material. The focused services below address common product-specific questions while retaining the need to evaluate the actual formulation.
Testing for plasma-derived protein preparations, with attention to protein concentration, stabilizers and the sample stage. Provide the formulation and any existing suitability data when planning a new test or reviewing an established procedure.
Focused product services:
Endotoxin Testing in Human Albumin
Endotoxin Testing in Immunoglobulins
Testing for recombinant protein samples from purification and development workflows. The expression system, purification history, protein concentration and formulation help define the preparation strategy and reporting units.
Focused product services:
Endotoxin Testing in Monoclonal Antibodies
Endotoxin Testing in Recombinant Coagulation Factors
Discuss testing for peptide materials and formulated preparations. Solvent composition, solubility, concentration and any reconstitution procedure are useful starting information for selecting suitable preparation and assay conditions.
Plan testing around the vaccine material, development stage and full formulation. Provide details of antigen preparations, adjuvants or other formulation components, together with the purpose of the endotoxin measurement.
Focused product service:
Endotoxin Testing in DNA Vaccines
Discuss endotoxin testing for nucleic acid materials, including plasmid DNA preparations. Identify the material, concentration, purification stage and formulation. For formulated or complexed samples, describe the carrier as well as the nucleic acid.
A broader entry point for biological drug substances, formulated products and samples that span several categories. Share the product composition and intended use so that the relevant testing work can be identified without assuming one approach fits every biologic.
Begin with a feasibility discussion covering the radionuclide, activity, formulation, sample condition and testing schedule. Handling arrangements and the analytical approach must be confirmed before shipment. Please contact our team to confirm whether the proposed material and timeline can be accommodated.
The comparison below identifies information useful for planning. It does not assign a fixed assay, dilution or acceptance limit to an entire product class.
On smaller screens, scroll horizontally to view all comparison columns.
| Product family | Information to provide | Preparation or assay consideration | Useful project question |
|---|---|---|---|
| Plasma-derived proteins | Protein identity, concentration and stabilizers | Evaluate matrix interference in the actual preparation | Can the target limit be assessed at a suitable dilution? |
| Recombinant proteins and antibodies | Expression source, purification stage and formulation | Account for concentration, buffers and process-related components | Is the aim a sample assessment or a comparison across purification stages? |
| Peptides | Material form, solvent and reconstitution conditions | Maintain a representative, assay-compatible sample preparation | How should the supplied material be prepared for testing? |
| Vaccines and DNA vaccines | Product type, formulation and stage of development | Assess the complete matrix rather than assuming antigen identity predicts suitability | Does the existing procedure address this formulation? |
| Nucleic acids | DNA or RNA identity, concentration and carrier, if present | Define preparation and units for the actual sample | How will the result relate to sample volume, material mass or intended use? |
| Other biopharmaceuticals | Active components, excipients and testing objective | Select an approach for the combined formulation | Which product-specific suitability work is needed? |
| Radiopharmaceuticals | Radionuclide, activity, formulation and sample condition | Confirm handling feasibility and timing before sample transfer | Can the proposed sample and schedule be accommodated? |
LAL gel-clot, turbidimetric, chromogenic and recombinant reagent-based approaches may offer different ways to address the same endotoxin question. The product name alone is not a method-selection rule. Review the required result alongside sample interference, preparation and the applicable dilution constraints.
| Your project situation | A useful next step |
|---|---|
| A new product or formulation | Review composition and the target limit, then assess method suitability before applying routine conditions. |
| A concentrated or complex sample | Evaluate preparation and dilution within the maximum valid dilution (MVD). Do not assume more dilution always produces a useful result. |
| A comparison across process stages | Identify the sampling points and agree on reporting units. Changes in concentration or matrix need to be considered when comparing results. |
| A modified buffer, excipient or concentration | Provide the original procedure and the formulation changes so that the need for additional suitability work can be reviewed. |
| An existing result that is difficult to interpret | Share controls, dilutions, sample handling details and the calculation basis. Review test validity before attributing differences to the product. |
Please provide the product identity and source, sample form, concentration, formulation, available quantity and sample count. Include the intended use, target endotoxin specification, requested units and any previous assay or interference data. For a reconstituted material, provide the diluent and preparation instructions.
For an injectable product, the intended route and dose may be relevant to the endotoxin specification. A research requirement and a regulated product specification are not automatically interchangeable. The proposed scope, sample requirements and schedule are confirmed during project review.
Not automatically. Formulation and concentration can affect assay performance even when the active ingredient is the same. An existing method is useful starting information, but its suitability for the submitted preparation needs to be considered.
Use the plasma-derived protein route for the relevant immunoglobulin preparation and the monoclonal antibody route for a recombinant monoclonal product. Both are proteins, but the source, formulation and project objective help identify the more useful service entry.
Start with the DNA vaccine service when vaccine development is the intended application. For a general plasmid or other nucleic acid preparation, use the nucleic acid service. Provide the formulation and purpose so that the scope can be defined consistently.
No. The relevant specification depends on the material and intended use, including applicable product requirements. A value used for one research preparation or product should not be copied to another solely because both belong to the same category.
No. Converting between these units requires the corresponding concentration or dose information and a consistent calculation basis. Include the sample concentration and desired reporting units when requesting testing.
No. It supports interpretation under the tested conditions, but does not by itself address every question about storage, holding time or formulation-related recovery. Describe any specific recovery concern so that suitable additional work can be discussed.
No. First provide the radionuclide, activity, formulation, sample condition and proposed schedule. Sample acceptance and handling arrangements must be confirmed before shipment; a general service enquiry is not approval to send radioactive material.
No. Bacterial endotoxin testing does not establish sterility or the absence of non-endotoxin pyrogens. Additional testing depends on the product risk assessment and intended application.
Send us your product identity, formulation and testing objective. Our team will review the sample information and discuss a suitable scope, reporting approach and project quotation.
Explore All Endotoxin Testing Services →
References
